95 related articles for article (PubMed ID: 26703448)
1. A novel pharmacokinetic model based on the complex elimination of monoclonal antibodies for bevacizumab pharmacokinetic study in rabbits.
Wang L; Ji S; Li M; Cheng Z
Int Immunopharmacol; 2016 Feb; 31():39-44. PubMed ID: 26703448
[TBL] [Abstract][Full Text] [Related]
2. A New Model to Describe the Single-dose Pharmacokinetics of Bevacizumab and Predict Its Multiple-Dose Pharmacokinetics in Beagle Dogs.
Li M; Qiang W; Wen Z; Li L; Wang L; Cheng Z
Iran J Pharm Res; 2019; 18(3):1147-1155. PubMed ID: 32641928
[TBL] [Abstract][Full Text] [Related]
3. Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkey.
Hardiansyah D; Ng CM
Eur J Pharm Sci; 2018 Dec; 125():130-141. PubMed ID: 30248389
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.
Papachristos A; Karatza E; Kalofonos H; Sivolapenko G
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32466535
[TBL] [Abstract][Full Text] [Related]
5. A novel model for the pharmacokinetic studies of bevacizumab and etanercept in healthy volunteers and patients.
Li M; Qiang W; Hu L; Wang L; Cheng Z
Biochem Pharmacol; 2017 Dec; 145():169-177. PubMed ID: 28822784
[TBL] [Abstract][Full Text] [Related]
6. An apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism.
Wang K; Stark FS; Schlothauer T; Lahr A; Cosson V; Zhi J; Habben K; Tessier J; Schick E; Staack RF; Krieter O
Cancer Chemother Pharmacol; 2017 Apr; 79(4):661-671. PubMed ID: 28314990
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon.
Li J; Gupta M; Jin D; Xin Y; Visich J; Allison DE
Cancer Chemother Pharmacol; 2013 Mar; 71(3):575-80. PubMed ID: 23228985
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of intravitreal bevacizumab (Avastin).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Singh RJ
Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
[TBL] [Abstract][Full Text] [Related]
9. Allometric Scaling of Therapeutic Monoclonal Antibodies Using Antigen Concentration as a Correction Factor: Application to the Human Clearance Prediction.
Wang L; Qiang W; Cheng Z
J Pharm Sci; 2016 Mar; 105(3):1335-40. PubMed ID: 26886347
[TBL] [Abstract][Full Text] [Related]
10. Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics.
Lovett ML; Wang X; Yucel T; York L; Keirstead M; Haggerty L; Kaplan DL
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):271-8. PubMed ID: 25592326
[TBL] [Abstract][Full Text] [Related]
11. Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
Azzopardi N; Dupuis-Girod S; Ternant D; Fargeton AE; Ginon I; Faure F; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Leguy-Seguin V; Rivière S; Corre R; Bailly S; Paintaud G
MAbs; 2015; 7(3):630-7. PubMed ID: 25751241
[TBL] [Abstract][Full Text] [Related]
12. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
[TBL] [Abstract][Full Text] [Related]
13. Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis.
Iwamoto N; Hamada A; Shimada T
Anal Biochem; 2018 Jan; 540-541():30-37. PubMed ID: 29128290
[TBL] [Abstract][Full Text] [Related]
14. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S
Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Yagi Y; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Fujita H; Ninomiya I; Fujimura T; Kayahara M; Kinuya S; Yashiro M; Hirakawa K; Ohta T
Cancer Chemother Pharmacol; 2010 Sep; 66(4):745-53. PubMed ID: 20033809
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors.
Xin Y; Li J; Wu J; Kinard R; Weekes CD; Patnaik A; Lorusso P; Brachmann R; Tong RK; Yan Y; Watts R; Bai S; Hegde PS
Clin Cancer Res; 2012 Nov; 18(21):6040-8. PubMed ID: 22962439
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
Nomoto H; Shiraga F; Kuno N; Kimura E; Fujii S; Shinomiya K; Nugent AK; Hirooka K; Baba T
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
[TBL] [Abstract][Full Text] [Related]
18. Aqueous humor concentration of bevacizumab after subconjunctival injection in rabbit.
Kim MJ; Han ES; Kim J; Kim TW
J Ocul Pharmacol Ther; 2010 Feb; 26(1):49-53. PubMed ID: 20148650
[TBL] [Abstract][Full Text] [Related]
19. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
[TBL] [Abstract][Full Text] [Related]
20. Safety of intravitreal injection of bevacizumab in rabbit eyes.
Feiner L; Barr EE; Shui YB; Holekamp NM; Brantley MA
Retina; 2006 Oct; 26(8):882-8. PubMed ID: 17031287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
